全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Search for Anti-EA(D) Antibodies in Subjects with an “Isolated VCA IgG” Pattern

DOI: 10.1155/2010/695104

Full-Text   Cite this paper   Add to My Lib

Abstract:

The presence of an “isolated viral capsid antigen (VCA) IgG” pattern in serum is not easy to interpret without the aid of further tests, such as specific immunoblotting or a virus genome search, that often give rise to organisational and economic problems. However, one alternative is to use an enzyme-linked immunosorbent assay (ELISA) to detect anti-early antigen (EA) antibodies, which can be found in about 85% of subjects with acute Epstein-Barr virus (EBV) infections. The purpose of this work was to search for anti-EA(D) antibodies in 130 samples with an isolated VCA IgG pattern at ELISA screening and classified as being indicative of past (102 cases) or acute (28 cases) infection on the basis of the immunoblotting results. Thirty-seven samples (28.5%) were positive for anti-EA(D), of which 25 (89.3%) had been classified by immunoblotting as indicating acute and 12 (11.8%) past EBV infection. This difference was statistically significant ( ). The results of our search for anti-EA(D) antibodies correctly identified nearly 90% of acute (presence) or past EBV infections (absence). When other tests are not available, the search for anti-EA antibodies may therefore be helpful in diagnosing patients with an isolated VCA IgG pattern at screening tests. 1. Introduction The most common manifestation of primary Epstein-Barr virus (EBV) infection is acute infectious mononucleosis, a self-limited clinical syndrome that most frequently affects adolescents and young adults. Serology is one of the cardinal means of diagnosing EBV infection as antibody search for viral capsid antigen (VCA), nuclear antigen (EBNA), and early antigen (EA) makes it possible to define the status of the infection [1, 2]. The three parameters of VCA IgG, VCA IgM, and EBNA-1 IgG generally make it simple to distinguish acute and past infection in immunocompetent patients [3]. The presence of VCA IgG and VCA IgM in the absence of EBNA-1 IgG is indicative of acute infection, whereas the presence of VCA IgG and EBNA-1 IgG in the absence of VCA IgM is typical of past infection. However, the presence of an isolated VCA IgG pattern may appear in about 8% of all subjects with at least one EBV infection marker [4] and may be difficult to interpret because it can be found in patients with prior infection as well as in those with acute infection. In fact, in some cases, VCA IgM may appear 1-2 weeks after VCA IgG, or for a very short time, or at such a low concentration as to be missed by conventional laboratory tests [5]; furthermore, VCA IgM may persist for a long time after acute infection and still

References

[1]  K. F. Macsween and D. H. Crawford, “Epstein-Barr virus—recent advances,” Lancet Infectious Diseases, vol. 3, no. 3, pp. 131–140, 2003.
[2]  A. Svahn, M. Magnusson, L. J?gdahl, L. Schloss, G. Kahlmeter, and A. Linde, “Evaluation of three commercial enzyme-linked immunosorbent assays and two latex agglutination assays for diagnosis of primary Epstein-Barr virus infection,” Journal of Clinical Microbiology, vol. 35, no. 11, pp. 2728–2732, 1997.
[3]  B. C. G?rtner, R. D. Hess, D. Bandt, A. Kruse, A. Rethwilm, K. Roemer, and N. Mueller-Lantzsch, “Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method,” Clinical and Diagnostic Laboratory Immunology, vol. 10, no. 1, pp. 78–82, 2003.
[4]  M. de Paschale, C. Agrappi, M. T. Manco, P. Mirri, E. F. Viganò, and P. Clerici, “Seroepidemiology of EBV and interpretation of the "isolated VCA IgG" pattern,” Journal of Medical Virology, vol. 81, no. 2, pp. 325–331, 2009.
[5]  G. Bauer, “The rational basis for efficient Epstein-Barr virus (EBV) serology,” Clinical Laboratory, vol. 41, no. 9, pp. 623–634, 1995.
[6]  M. Kampmann, K. Henninger, and G. Bauer, “Determination of antibodies directed specifically against Epstein-Barr virus nuclear antigen-1 (EBNA-1) by anticomplementary immunofluorescence (ACIF),” Medical Microbiology Letters, vol. 2, pp. 1–8, 1993.
[7]  G. Bauer, “Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology,” Clinical Laboratory, vol. 47, no. 5-6, pp. 223–230, 2001.
[8]  V. Vetter, L. Kreutzer, and G. Bauer, “Differentiation of primary from secondary anti-EBNA-1-negative cases by determination of avidity of VCA-IgG,” Clinical and Diagnostic Virology, vol. 2, no. 1, pp. 29–39, 1994.
[9]  R. D. Hess, “Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years,” Journal of Clinical Microbiology, vol. 42, no. 8, pp. 3381–3387, 2004.
[10]  K. H. Chan, M. H. Ng, W. H. Seto, and J. S. M. Peiris, “Epstein-Barr Virus (EBV) DNA in sera of patients with primary EBV infection,” Journal of Clinical Microbiology, vol. 39, no. 11, pp. 4152–4154, 2001.
[11]  R. Luderer, M. Kok, H. G. M. Niesters, R. Schuurman, O. de Weerdt, and S. F. T. Thijsen, “Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation,” Molecular Diagnosis, vol. 9, no. 4, pp. 195–200, 2005.
[12]  R. D. Holmes and R. J. Sokol, “Epstein-Barr virus and post-transplant lymphoproliferative disease,” Pediatric Transplantation, vol. 6, no. 6, pp. 456–464, 2002.
[13]  J. Schubert, W. Zens, and B. Weissbrich, “Comparative evaluation of the use of immunoblots and of IgG avidity assays as confirmatory tests for the diagnosis of acute EBV infections,” Journal of Clinical Virology, vol. 11, no. 3, pp. 161–172, 1998.
[14]  E. T. Lennette and W. Henle, “Epstein-Barr virus infections: clinical and serologic feature,” Laboratory Management, vol. 25, pp. 23–26, 1987.
[15]  W. Henle and G. Henle, “Epstein-Barr virus-specific serology in immunologically compromised individuals,” Cancer Research, vol. 41, no. 11, pp. 4222–4225, 1981.
[16]  P. V. Coyle, D. Wyatt, J. H. Connolly, and G. A. Lynch, “Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma in Northern Ireland,” Irish Journal of Medical Science, vol. 156, no. 6, pp. 182–184, 1987.
[17]  E. T. Lennette, “Epstein-Barr virus (EBV),” in Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections, E. H. Lennette, D. A. Lennette, and E. T. Lennette, Eds., pp. 299–312, American Public Health Association, Washington, DC, USA, 1995.
[18]  P. Wohlrabe, I. Farber, P. Wutzler, and R. Uhlig, “Antibodies to Epstein-Barr virus-induced early antigens in blood donors,” Acta Virologica, vol. 33, no. 4, pp. 344–348, 1989.
[19]  D. W. T. Ho, P. R. Field, and A. L. Cunningham, “Rapid diagnosis of acute Epstein-Barr virus infection by an indirect enzyme-linked immunosorbent assay for specific immunoglobulin M (IgM) antibody without rheumatoid factor and specific IgG interference,” Journal of Clinical Microbiology, vol. 27, no. 5, pp. 952–958, 1989.
[20]  J. S. Klutts, B. A. Ford, N. R. Perez, and A. M. Gronowski, “Evidence-based approach for interpretation of Epstein-Barr virus serological patterns,” Journal of Clinical Microbiology, vol. 47, no. 10, pp. 3204–3210, 2009.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133